Roots Analysis

FEBRUARY 13, 2023

Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

OCTOBER 19, 2020

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Testing Therapies, Antivirals and Vaccines. There has been some discussion of running challenge trials for COVID-19 vaccines. Please read more here. .

Vaccine 52

Vaccine Vaccination Trials Clinical Trials 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Roots Analysis

AUGUST 16, 2023

The success of COVID-19 vaccines paved the path for mRNA-based drug products. Market Landscape of mRNA Synthesis Kits Presently more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs with yield range up to 50,000 µg, are currently available in the market.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing RNA 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Horizon Discovery Group – U.K.-based for its cGMP-compliant CHOSOURCE platform.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Roots Analysis

AUGUST 15, 2023

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52

Protein In-Vitro Production Reagent 52

The Pharma Data

DECEMBER 23, 2020

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. BioNTech – Germany’s BioNTech and partner Pfizer secured authorization from the European Medicines Agency for its COVID-19 vaccine. It is a division of Gamma Biosciences.

Drugs 52

Drugs Licensing Licensing Vaccination 52

The Pharma Data

DECEMBER 30, 2020

“Even with the roll-out of vaccines, the need for fast, accurate, high-volume COVID-19 testing will continue for the foreseeable future,” said Dr. Sarj Patel, President of FYR. Adding FYR as a primary testing resource will keep test processing within Montana and alleviate pressure on the state laboratory in Helena.

Reagent 52

Reagent Life Science Development Vaccination 52

The Pharma Data

MARCH 16, 2022

2 subvariant is steadily increasing in prevalence, specifically in Denmark Use of these tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines and public health interventions All Roche SARS-Cov-2 tests correctly identify the virus including these new subvariants. 3 and Delta. “In

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

Roots Analysis

OCTOBER 16, 2023

Further, the labor and reagent cost incurred in cloning procedures is reduced with customized cloning. Several biopharmaceutical players have collaborated and contributed to the research and development of different products, such as DNA cloning kits, vaccines and treatment solutions to combat COVID 19.

DNA 40

DNA Gene Protein In-Vitro 40

The Pharma Data

MAY 15, 2023

Before joining Solvias Group, Karen held various senior leadership roles at Novartis, including global head investor relations from 2000 to 2006, head M&A and Executive Committee member, as well as site head for the Vaccines & Diagnostics division between 2006 and 2011.

Sales 40

Sales Production Doctors Doctor 40

The Pharma Data

JANUARY 22, 2021

Next on the agenda: speeding up the nation’s vaccine rollout. To help do so, he’s directed the Federal Emergency Management Agency to begin constructing federally supported community vaccination centers, with the goal of having 100 centers in operation within the next month, The New York Times reported.

Vaccine 52

Vaccine Vaccination Antibody Reagent 52

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. This is also expected to provide greater flexibility for potential distribution partners.

Genetics 40

Genetics Reagent Biobanking Production 40

XTalks

MARCH 11, 2025

Advances in mRNA quantification are paving the way for improved vaccine analytics a critical component as the industry shifts toward multivalent mRNA vaccines. These vaccines can be engineered to address antigenic variability and stimulate a wide-ranging immune response.

Vaccine 64

Vaccine Vaccination Development Manufacturing 64

XTalks

JANUARY 6, 2025

Biomanufacturing and Automation The production of vaccines, drugs and diagnostic reagents increasingly depends on good manufacturing practice (GMP) facilities for the manufacturing of critical reagents, a reliance that has intensified since the pandemic. percent from 2021 to 2031, reaching an estimated value of $85.2

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

The Pharma Data

JANUARY 21, 2021

He’ll also issue executive orders that aim to ramp up the production and distribution of COVID-19 tests and vaccines, make schools and travel safer, and help states fight the spread of coronavirus. The new plan also steers more money to states, which have complained they need more funding to test and vaccinate residents.

Vaccine 52

Vaccine Vaccination Antibody Reagent 52